(Q28142638)

1

0 references

J Garau

2

0 references

H Lode

3

0 references

K V Rolston

4

0 references

S E Wilson

5

0 references

J P Quinn

International Journal of Antimicrobial Agents

6

0 references

language of work or name

English

0 references

publication date

February 1999

0 references

published in

0 references

volume

11

0 references

issue

2

0 references

page(s)

93-100

0 references

cites work

Meropenem: a microbiological overview

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Beta-lactamase-mediated resistance and opportunities for its control

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

APACHE II score and abdominal sepsis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Selecting therapy for serious infections in children: maximizing safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Imipenem/cilastatin treatment of bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Pseudomonas bacteremia. Retrospective analysis of 410 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021

Expanding the options for risk-based therapy in febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900094-6

7 January 2021